AGILON HEALTH INC (AGL) Fundamental Analysis & Valuation

NYSE:AGL • US00857U1079

Current stock price

30.05 USD
-0.89 (-2.88%)
At close:
29.01 USD
-1.04 (-3.46%)
After Hours:

This AGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. AGL Profitability Analysis

1.1 Basic Checks

  • AGL had negative earnings in the past year.
  • AGL had a negative operating cash flow in the past year.
  • AGL had negative earnings in each of the past 5 years.
  • AGL had a negative operating cash flow in each of the past 5 years.
AGL Yearly Net Income VS EBIT VS OCF VS FCFAGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • With a Return On Assets value of -30.78%, AGL is not doing good in the industry: 84.00% of the companies in the same industry are doing better.
  • AGL's Return On Equity of -308.79% is on the low side compared to the rest of the industry. AGL is outperformed by 80.00% of its industry peers.
Industry RankSector Rank
ROA -30.78%
ROE -308.79%
ROIC N/A
ROA(3y)-20.29%
ROA(5y)-18.56%
ROE(3y)-134.57%
ROE(5y)-90.24%
ROIC(3y)N/A
ROIC(5y)N/A
AGL Yearly ROA, ROE, ROICAGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • AGL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGL Yearly Profit, Operating, Gross MarginsAGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. AGL Health Analysis

2.1 Basic Checks

  • AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • AGL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, AGL has more shares outstanding
  • The debt/assets ratio for AGL is higher compared to a year ago.
AGL Yearly Shares OutstandingAGL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
AGL Yearly Total Debt VS Total AssetsAGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • AGL has an Altman-Z score of 1.66. This is a bad value and indicates that AGL is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of AGL (1.66) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.12 indicates that AGL is not too dependend on debt financing.
  • AGL has a Debt to Equity ratio of 0.12. This is in the better half of the industry: AGL outperforms 73.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 1.66
ROIC/WACCN/A
WACC9.23%
AGL Yearly LT Debt VS Equity VS FCFAGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • AGL has a Current Ratio of 1.02. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.02, AGL is doing worse than 72.00% of the companies in the same industry.
  • A Quick Ratio of 1.02 indicates that AGL should not have too much problems paying its short term obligations.
  • AGL's Quick ratio of 1.02 is on the low side compared to the rest of the industry. AGL is outperformed by 65.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
AGL Yearly Current Assets VS Current LiabilitesAGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AGL Growth Analysis

3.1 Past

  • AGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.79%.
  • Looking at the last year, AGL shows a decrease in Revenue. The Revenue has decreased by -2.11% in the last year.
  • Measured over the past years, AGL shows a very strong growth in Revenue. The Revenue has been growing by 37.25% on average per year.
EPS 1Y (TTM)-50.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.92%
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y29.87%
Revenue growth 5Y37.25%
Sales Q2Q%3.09%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.37% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 5.84% on average over the next years.
EPS Next Y75.03%
EPS Next 2Y34.37%
EPS Next 3Y25.37%
EPS Next 5YN/A
Revenue Next Year-6.34%
Revenue Next 2Y-1.2%
Revenue Next 3Y3.2%
Revenue Next 5Y5.84%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AGL Yearly Revenue VS EstimatesAGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B
AGL Yearly EPS VS EstimatesAGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

1

4. AGL Valuation Analysis

4.1 Price/Earnings Ratio

  • AGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGL Price Earnings VS Forward Price EarningsAGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGL Per share dataAGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200 300

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AGL's earnings are expected to grow with 25.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.37%
EPS Next 3Y25.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AGL Dividend Analysis

5.1 Amount

  • No dividends for AGL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AGL Fundamentals: All Metrics, Ratios and Statistics

AGILON HEALTH INC

NYSE:AGL (4/17/2026, 8:04:00 PM)

After market: 29.01 -1.04 (-3.46%)

30.05

-0.89 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-25
Earnings (Next)05-06
Inst Owners65.46%
Inst Owner Change-100%
Ins Owners3.07%
Ins Owner Change17.07%
Market Cap499.13M
Revenue(TTM)5.93B
Net Income(TTM)-391.35M
Analysts55
Price Target21.99 (-26.82%)
Short Float %N/A
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-69.2%
Min EPS beat(2)-69.54%
Max EPS beat(2)-68.86%
EPS beat(4)1
Avg EPS beat(4)42.36%
Min EPS beat(4)-114.66%
Max EPS beat(4)422.51%
EPS beat(8)3
Avg EPS beat(8)2.31%
EPS beat(12)4
Avg EPS beat(12)-2.5%
EPS beat(16)4
Avg EPS beat(16)-25.3%
Revenue beat(2)1
Avg Revenue beat(2)3.07%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)6.33%
Revenue beat(4)2
Avg Revenue beat(4)0.23%
Min Revenue beat(4)-6.13%
Max Revenue beat(4)6.33%
Revenue beat(8)2
Avg Revenue beat(8)-1.09%
Revenue beat(12)6
Avg Revenue beat(12)0.54%
Revenue beat(16)10
Avg Revenue beat(16)1.1%
PT rev (1m)2087.31%
PT rev (3m)2087.31%
EPS NQ rev (1m)2142.25%
EPS NQ rev (3m)4457.02%
EPS NY rev (1m)-1591.09%
EPS NY rev (3m)-1293.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.11%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-8.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.08
P/FCF N/A
P/OCF N/A
P/B 3.94
P/tB 8.18
EV/EBITDA N/A
EPS(TTM)-23.75
EYN/A
EPS(NY)-5.93
Fwd EYN/A
FCF(TTM)-8.96
FCFYN/A
OCF(TTM)-6.37
OCFYN/A
SpS357.17
BVpS7.63
TBVpS3.67
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -30.78%
ROE -308.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.29%
ROA(5y)-18.56%
ROE(3y)-134.57%
ROE(5y)-90.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover4.67
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 150.76%
Cap/Sales 0.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z 1.66
F-Score4
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)157.46%
Cap/Depr(5y)160.22%
Cap/Sales(3y)0.71%
Cap/Sales(5y)0.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.92%
EPS Next Y75.03%
EPS Next 2Y34.37%
EPS Next 3Y25.37%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y29.87%
Revenue growth 5Y37.25%
Sales Q2Q%3.09%
Revenue Next Year-6.34%
Revenue Next 2Y-1.2%
Revenue Next 3Y3.2%
Revenue Next 5Y5.84%
EBIT growth 1Y-48.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year91.85%
EBIT Next 3Y29.68%
EBIT Next 5Y18.78%
FCF growth 1Y-50.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.05%
OCF growth 3YN/A
OCF growth 5YN/A

AGILON HEALTH INC / AGL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of AGILON HEALTH INC (AGL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to AGL.


What is the valuation status of AGILON HEALTH INC (AGL) stock?

ChartMill assigns a valuation rating of 1 / 10 to AGILON HEALTH INC (AGL). This can be considered as Overvalued.


How profitable is AGILON HEALTH INC (AGL) stock?

AGILON HEALTH INC (AGL) has a profitability rating of 0 / 10.


Can you provide the financial health for AGL stock?

The financial health rating of AGILON HEALTH INC (AGL) is 2 / 10.